Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China · Delayed Price · Currency is CNY 53.23
-0.71 (-1.32%)
At close: Feb 26, 2026
SHA:688193 Revenue
Shanghai Rendu Biotechnology had revenue of 37.91M CNY in the quarter ending September 30, 2025, a decrease of -13.76%. This brings the company's revenue in the last twelve months to 165.86M, down -6.80% year-over-year. In the year 2024, Shanghai Rendu Biotechnology had annual revenue of 177.35M with 7.87% growth.
Revenue (ttm)
165.86M
Revenue Growth
-6.80%
P/S Ratio
12.68
Revenue / Employee
495.11K
Employees
290
Market Cap
2.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 177.35M | 12.94M | 7.87% |
| Dec 31, 2023 | 164.41M | -139.44M | -45.89% |
| Dec 31, 2022 | 303.85M | 11.54M | 3.95% |
| Dec 31, 2021 | 292.31M | 42.40M | 16.97% |
| Dec 31, 2020 | 249.90M | 150.74M | 152.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Maccura Biotechnology Co.Ltd | 2.21B |
| Shanghai Labway Clinical Laboratory | 1.52B |
| Medicalsystem Biotechnology | 1.47B |
| Beijing Strong Biotechnologies,Inc. | 1.43B |
| Thalys Medical Technology Group | 1.25B |
| Amoy Diagnostics | 1.13B |
| Berry Genomics Co.,Ltd | 941.16M |
| SMO ClinPlus CO.,LTD. | 819.09M |